Biocon Biologics to launch Trastuzumab, Nivolumab, Pembrolizumab biosimilars for cancer. Expanding oncology portfolio.
Beyond hazard ratios, investigators used restricted mean survival time (RMST) analysis to compare survival gains across trialed ICI combinations for mRCC.
Immune checkpoint inhibitors have significantly improved survival for a variety of malignancies over the past decade, but the costs of these medications have barely changed.An investigation into 11 ...
Biocon Biologics plans to introduce three oncology biosimilars, enhancing its cancer treatment portfolio. They will unveil ...
CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...
He will also participate in a fireside chat at the ENDPOINTS at JPM26 conference on Tuesday, January 13 titled, "Achieving ...
Gastrointestinal (GI) Cancers Symposium, Dani Castillo, MD, medical oncologist, City of Hope, shared new research titled, “Impact of metastatic sites and Lauren subtype on survival outcomes of ...
Trastuzumab, Nivolumab and Keytruda: Our Bureau, Bengaluru Wednesday, January 7, 2026, 11:30 Hrs [IST] Biocon Biologics, ...
Pivotal Phase 3 trial of MO-03 builds on prior studies that demonstrated enhanced immunotherapy benefit without added ...
Also highlight plans to integrated with Biocon at 44th Annual J.P. Morgan Healthcare Conference in San Francisco ...
Key stocks like Adani Green, Titan, and Biocon are poised for growth due to strategic expansions and strong project ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback